Giredestrant

News

Roche extols 'unprecedented' result with breast cancer drug

Roche's oral SERD giredestrant has achieved what the company says is a stellar result as adjuvant treatment for early breast cancer.

News

ESMO: Clear air emerges between Roche SERD and its rivals

Has Roche taken a lead in the oral SERD category of breast cancer therapies with data showing activity in wild-type ESR1 patients?

News

Roche's oral SERD comes good in 2nd-line breast cancer trial

Roche has staked a claim to use its oral SERD giredestrant as a second-line therapy for breast cancer, regardless of a patient's ESR1 mutation status.

News

Data cues up AZ oral SERD filing in first-line breast cancer

AstraZeneca could be the first to bring an oral SERD to market in first-line breast cancer after camizestrant hit the mark in a phase 3 trial.

News

Roche's oral SERD giredestrant fails breast cancer trial

Roche revealed in its first-quarter results statement that giredestrant missed the mark in the phase 2 acelERA trial in advanced breast cancer, in what appears to be another blow to the eme

News

ESMO21: Roche's giredestrant takes stage in battle of the or...

Roche has revealed the first phase 2 clinical data with giredestrant, one of a clutch of new selective oestrogen receptor degraders (SERDs) hoping to provide an oral alternative to AstraZen

Roche extols 'unprecedented' result with breast cancer drug

ESMO: Clear air emerges between Roche SERD and its rivals

Roche's oral SERD comes good in 2nd-line breast cancer trial

Data cues up AZ oral SERD filing in first-line breast cancer

Roche's oral SERD giredestrant fails breast cancer trial

ESMO21: Roche's giredestrant takes stage in battle of the or...

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Giredestrant

Editor's Picks